Somaxon's shares crash on FDA complete response letter for insomnia drug Silenor
This article was originally published in Scrip
Executive Summary
Somaxon has been dealt another blow after the US FDA issued it with a complete response letter for its lead drug candidate, the insomnia drug Silenor (doxepin), stating that it cannot be approved in its present form.